Developing antimicrobial peptide-drug conjugates to treat superbugs

Antimicrobial-resistant (AMR) pathogens are a growing global health concern, responsible for 1.27 million deaths in 2019. By 2050 AMR pathogens are expected to take the lives of 10 million people each year, with a global financial cost exceeding $US1 trillion. The current treatment of AMR pathogens requires lengthy, costly and, often dangerous, antibiotic regimes. Currently, AMR pathogens are circulating for every available antibiotic.

Long-term global use of antibiotics results in significant selection pressure on the target bacteria, leading to a favourable selection of resistant organisms and spreading AMR from person to person. Pharmaceutical companies are stepping away from antibiotic development due to the associated cost and short therapeutic window. Ineffective antibiotics enable AMR pathogens to survive in the host for longer, contributing to increased suffering, disability and mortality.

There is an urgent, unmet requirement for new antimicrobial agents that are active against AMR pathogens and are designed to reduce resistance development.


  • Develop antimicrobial peptide-based antibiotics to treat superbugs.

Research team

Take part in this project

Student applications

Students who are applying to study at The Florey can register their interest in this project. Refer to our step-by-step guide to help you with your application.

How to apply

Accepting students

Contact us

If you’re interested in learning more about this project please contact our team.

Please enter your first name
Please enter your last name
Please enter a valid phone number
Please enter a correct email address
Please provide information regarding your enquiry